Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649242 · ClinicalTrials.gov registry record · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
A Phase 3 study of Pediatric Migraine, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,100
- Enrollment target
- 20
- Study locations
NCT04649242 is a Phase 3 study of Pediatric Migraine that is actively recruiting participants, run by Pfizer. The registered enrollment target is 2,100 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT04649242, a Phase 3 study of Pediatric Migraine, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Conditions Studied
Interventions
- DRUG Matching placebo
- DRUG Rimegepant/BHV3000
Study Locations (20)
California
- Advanced Research Center, Inc. - Anaheim
- Adult & Child Neurology Medical Associates - Costa Mesa
- ProScience Research Group - Culver City
- Memorial Health Services - Fountain Valley
- Neuro-Pain Medical Center - Fresno
- Regents of the University of California (UC San Diego) - La Jolla
- Adult & Child Neurology Medical Associates - Long Beach
- Miller Children's & Women's Hospital Long Beach - Long Beach
- National Research Institute - Los Angeles
- Velocity Clinical Research - North Hollywood - North Hollywood
- Children's Hospital of Orange County - Inpatient Pharmacy - Orange
- Children's Hospital of Orange County - Neuroscience Center - Orange
- Children's Hospital of Orange County - Orange
- The Neurology Group - Pomona
- University of California, Davis Midtown Clinic - Sacramento
- UC Davis Medical Center, Investigational Drug Service (IDS) Pharmacy - Sacramento
- University of California, Davis Clinical and Translational Science Center Clinical Research (CCRC) - Sacramento
Arizona
- Perseverance Research Center, LLC - Scottsdale
- Physicians Research Group - Tempe
Alabama
- Achieve Clinical Research, LLC d/b/a Accel Research Sites-Neurology and Neurodiagnostic of Alabama - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,100 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2029-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04649242
The ClinicalTrials.gov registry entry for NCT04649242 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pediatric Migraine appearing as the primary indexed condition, and to 2 interventions - of which Matching placebo is the first listed.
NCT04649242 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT04649242 about?
NCT04649242 is a clinical study titled "Randomized Study in Children and Adolescents With Migraine: Acute Treatment". The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
What is the current status of trial NCT04649242?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,100 participants. The study started on 2021-01-15. Estimated completion is 2029-01-09.
What conditions does trial NCT04649242 study?
This clinical trial studies the following conditions: Pediatric Migraine.
What interventions are being tested in trial NCT04649242?
The interventions under investigation include: Matching placebo (DRUG), Rimegepant/BHV3000 (DRUG).
Who is sponsoring clinical trial NCT04649242?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04649242 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.